A phase III, randomized, controlled, observer-blind study to demonstrate effectiveness, immunogenicity and safety of GSK’s meningococcal Group B and combined ABCWY vaccines when administered to healthy adolescents and young adults
Participants needed: Enrolling Grade 12 (age 17-18 years) Grade 6 (age 11-12)
Meningococcal disease is caused by the bacteria Neisseria meningitidis and can result in very severe disease such as sepsis (blood infection) and meningitis. There are currently vaccines that protect against 4 different types (A, C, W, Y) being used across Canada and doctors want to protect against type B too
Enrolling Grade 12 (age 17-18 years) Grade 6 (age 11-12) who have not received a Men ACWY Vaccination in the last 4 years.
What is involved
Participants will receive a MenACWY + B vaccine. There will be 6 visits to the study clinic and 7 phone calls over the course of 12 months. These visits will include a physical exam, vaccinations, blood tests, and questions about your health.
Eligible participants will be reimbursed for travel/parking & receive a gift card at each visit.
NOTE: We ask that you review the information and consent form before volunteering for this study. After review, please contact us and someone will reply to your message with further information. The information and consent form will be reviewed with you during your first site visit before signing.